• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Immunovia

0.19 SEK

-1.45 %

Less than 1K followers

IMMNOV

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.45 %
+0.32 %
+16.44 %
-16.39 %
-26.72 %
-46.35 %
-74.67 %
-99.46 %
-98.22 %

Immunovia operates in the biotechnology industry and focuses on the development of diagnostic tools for the early detection of cancer. The company's research and development is focused on molecular diagnostics and its products are aimed at healthcare institutions and physicians. The business is global with a strong presence in Europe and North America. Immunovia was founded in 2007 and is headquartered in Lund.

Read more
Market cap
127.67M SEK
Turnover
200.18K SEK
Revenue
690K
EBIT %
-11,650.72 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Clark Kent got there first. Why wouldn’t I, as someone in a risk group, rather take CA19-9, which is even more sensitive? Not to mention the burden caused by false positives (well, that doesn’t bother the test seller, of course). For that $750 price, I would rather get a pancreatic...
9/17/2025, 2:54 PM
2
That is precisely the problem with tests of this kind. If a rare disease like pancreatic cancer is screened, the test should be very accurate to avoid unnecessary false positives. Since the layperson does not understand this and may happily buy the test, there is still that small...
9/17/2025, 7:27 AM
by Clark kent
2
Part of the Inova Health system, Inova Schar Cancer adopts Immunovia’s Pancreasure blood test MFN – 15 Sep 25 Immunovia: Inova Schar Cancer Adopts Immunovia’s PancreaSure Test... LUND, Sweden – Immunovia (publ.), the pancreatic cancer diagnostics company, today announced that its...
9/15/2025, 7:48 AM
by Kolothos Apollonia
2
It’s been a difficult target, with interesting fluctuations recently. And they certainly won’t calm down with the things you mentioned. Pharmaceutical companies offer excitement to life. I own some.
9/2/2025, 10:07 AM
by Cezeta
2
In familial cases, the sensitivity is the same 78%, the specificity is a bit better 94%, so the math is still quite unforgiving. If we consider that the prior probability of finding pancreatic cancer at a single point in time around age 50 is 10/100,000, and for someone with a family...
9/17/2025, 2:47 PM
by Clark kent
1
Approximately 1,000 new pancreatic cancer cases are diagnosed daily worldwide. Most of them too late.
9/17/2025, 1:13 PM
by Reissu
1
The test is initially targeted at risk groups. Pancreatic cancer took my father, so I would gladly go for that test even once a year. There are enough people in risk groups in the world, and the company is only worth about 20 million euros so far.
9/17/2025, 9:36 AM
by Reissu
1
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6/8
2026

Interim report Q2'26

5/11
2026

Interim report Q3'26

11/2
2027

Annual report '26

Press release6/15/2026, 5:30 AM

Immunovia presenterar nya prestandadata för PancreaSure inför kommande ansökan om Medicare-ersättning

Immunovia
Press release6/15/2026, 5:30 AM

Immunovia announces new performance data for PancreaSure ahead of upcoming application for Medicare coverage

Immunovia
Press release6/10/2026, 1:02 PM

Immunovia publicerar slutgiltiga resultat från AFFIRM-studien i Journal of Clinical Oncology som bekräftar stark diagnostisk prestanda för PancreaSure

Immunovia

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release6/10/2026, 1:02 PM

Immunovia publishes final AFFIRM study results in Journal of Clinical Oncology confirming strong diagnostic performance of PancreaSure

Immunovia
Regulatory press release6/10/2026, 8:12 AM

Finansinspektionen: Flaggningsmeddelande i Immunovia AB (publ)

Immunovia
Regulatory press release6/9/2026, 9:09 AM

Finansinspektionen: Flaggningsmeddelande i Immunovia AB (publ)

Immunovia
Regulatory press release6/8/2026, 7:24 AM

Finansinspektionen: Flaggningsmeddelande i Immunovia AB (publ)

Immunovia
Regulatory press release6/2/2026, 11:09 AM

Finansinspektionen: Flaggningsmeddelande i Immunovia AB (publ)

Immunovia
Regulatory press release5/22/2026, 8:58 AM

Finansinspektionen: Flaggningsmeddelande i Immunovia AB (publ)

Immunovia
Regulatory press release5/13/2026, 10:30 AM

KOMMUNIKÉ FRÅN ÅRSSTÄMMA DEN 13 MAJ 2026 I IMMUNOVIA AB (PUBL)

Immunovia
Regulatory press release5/13/2026, 10:30 AM

BULLETIN FROM THE ANNUAL GENERAL MEETING ON 13 MAY 2026 IN IMMUNOVIA AB (PUBL)

Immunovia
Press release5/11/2026, 6:25 AM

Carlsquare: Research update Immunovia, Q1 2026: Initial commercialisation phase on track

Immunovia
Regulatory press release5/7/2026, 7:10 AM

Rättelse: Immunovia publicerar Delårsrapport januari-mars 2026

Immunovia
Regulatory press release5/7/2026, 7:10 AM

Correction: Immunovia Publishes Interim Report for January-March 2026

Immunovia
Regulatory press release5/7/2026, 6:30 AM

Immunovia publicerar Delårsrapport januari-mars 2026

Immunovia
Regulatory press release5/7/2026, 6:30 AM

Immunovia Publishes Interim Report for January-March 2026

Immunovia
Regulatory press release5/6/2026, 8:02 AM

Finansinspektionen: Flaggningsmeddelande i Immunovia AB (publ)

Immunovia
Press release5/5/2026, 6:00 AM

Immunovia initierar registerstudien ASSURE för att utvärdera nyttan av PancreaSure vid övervakning av individer med hög risk för bukspottkörtelcancer

Immunovia
Press release5/5/2026, 6:00 AM

Immunovia launches ASSURE registry to evaluate real-world clinical impact of PancreaSure in high-risk pancreatic cancer surveillance

Immunovia
Press release5/4/2026, 5:00 AM

Immunovia invites to a presentation on the Q1 report and 2026 objectives

Immunovia